Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Issam Makhoul

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentInternal Med, College of Medicine
DivisionInternal Med Hem-Onc
Address523 Cancer Institute
4104 Outpatient Circle
Mail Slot # 508
Little Rock AR 72205
Phone501-526-6990 x8031
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Issam Makhoul, M.D., is Associate Professor and Director of the Division of Hematology Oncology in the Department of Internal Medicine at the University of Arkansas for Medical Sciences (UAMS). He is also the inaugral recipient of the Laura F. Hutchins, M.D. Endowed Chair for Hematology and Oncology. After receiving his medical degree from Tishreen University in Lattakia, Syria, Dr. Makhoul obtained a degree in Endocrinology and Metabolic Diseases from René Descartes University in Paris, France. Dr. Makhoul was a resident in internal medicine at Penn State Geisinger Medical Center in Danville, Pennsylvania. Afterwards, he completed a fellowship in Hematology/Oncology at Penn State Hershey Medical Center in Hershey, Pennsylvania. Dr. Makhoul is certified in internal medicine, medical oncology and hematology. He is a member of the American Society of Clinical Oncology, American Society of Hematology and the American Association for Cancer Research. His research interests include resistant breast cancer to hormonal therapy and chemotherapy, GI malignancies and quality of life in cancer patients.


    Collapse Research Funds 
    Collapse research activities
    R01CA236209     (TACKETT, ALAN)Jun 15, 2019 - May 31, 2024
    NIH/NCI
    Identification of Druggable Targets to Complement Melanoma Therapy
    Role: Co-Investigator

    CA209817     (ARNAOUTAKIS, KONSTANTINOS)Sep 13, 2018
    Bristol-Meyers Squibb
    A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer (CheckMate 817, CHECKpoint pathway and nivoluMAb clinical Trial Evaluation)
    Role: Principal Investigator

    U24CA215109     (PRIOR, FRED WILLIAM)Sep 22, 2017 - Jul 31, 2022
    NIH/NCI
    TCIA Sustainment and Scalability - Platforms for Quantitative Imaging Informatics in Precision Medicine
    Role: Co-Investigator

    CLEE011XUS10T     (MAKHOUL, ISSAM)Jan 31, 2017
    Kansas Medical Center Research Institute
    Femara (Letrozole) Plus Ribociclib (LEE011) or Placebo as Neo-adjuvant Endocrine Therapy for Women with ER-positive, HER2-negative Early Breast Cancer
    Role: Principal Investigator

    P20GM109005     (BOERMA, MARJAN)Jun 24, 2015 - Mar 31, 2020
    NIH/NIGMS
    Center for Studies of Host Response to Cancer Therapy
    Role: Co-Investigator

    Eval of Survival of Long Term Melanoma 203720     (MAKHOUL, ISSAM)Jan 5, 2015
    Amgen, Inc.
    A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects With Melanoma Who Previously Received Talimogene Laherparepvec
    Role: Principal Investigator

    NLG 0405     (MAKHOUL, ISSAM)Mar 22, 2013
    Newlink Genetics
    A Phase III study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute-Pancreas (algenpantucel-L) immunotherapy in Subjects with Surgicall
    Role: Principal Investigator

    MAVERICC     (MAKHOUL, ISSAM)Feb 7, 2012 - Feb 6, 2015
    Genentech, Inc.
    MAVERICC: A Randomized Phase II Study of Bevacizumab/mFOLFOX6 vs. Bevacizumab/FOLFIRI with BioMarker Stratification in Patients with Previously Untrea
    Role: Principal Investigator

    ABI-007     (MAKHOUL, ISSAM)Dec 19, 2011
    Abraxis BioScience, LLC
    A Randomized Phase III Study of Weekly ABI-007 plus Gemcitabine versus Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas
    Role: Principal Investigator

    T-DMI1     (MAKHOUL, ISSAM)Jun 20, 2011 - Jan 12, 2017
    Hoffmann-La Roche, Inc.
    A randomized, 3 arm, multicentre, phase III study to evaluate the efficacy and the safety of T-DM1 combined with pertuzumab or T-DM1 combined with per
    Role: Principal Investigator

    14T-MC-JVBB     (MAKHOUL, ISSAM)Feb 16, 2011
    Eli Lilly & Company
    A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B) Drug Prod
    Role: Principal Investigator

    CA182-034     (MAKHOUL, ISSAM)Jul 28, 2010 - Jul 27, 2012
    Bristol-Meyers Squibb
    Randomized, Double-blind, Multi-center Phase III Study of Birvanib plus Best Supportive Care (BSC) versus Placebo plus BSC in Subjects with Advanced H
    Role: Principal Investigator

    CA182-033     (MAKHOUL, ISSAM)Mar 9, 2010
    Bristol-Meyers Squibb
    A Randomized, Double-blind, Multi-center Phase III Study of Brivanib versus Sorafenib as First-line Treatment in Patients with Advanced Hepatocellular
    Role: Principal Investigator

    SN-38     (MAKHOUL, ISSAM)Jan 27, 2010
    3D Imaging, LLC
    Human Radiation Dosimetry of SN-38
    Role: Principal Investigator

    20050136     (MAKHOUL, ISSAM)Nov 16, 2006 - Nov 16, 2010
    Amgen, Inc.
    A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa ) in the Treatment of Bone Metastases in Subjects wit
    Role: Principal Investigator

    AG-013736 CTA     (MAKHOUL, ISSAM)Mar 7, 2006 - Feb 15, 2009
    Pfizer, Inc.
    A Randomized Phase II Study of the Anti-Angiogensis Agent AG-013736 in Combination with Gemcitabine in Patients with Chemotherapy-Naïve Advanced Pancr
    Role: Principal Investigator

    2004-59 AVF3290 CTA     (MAKHOUL, ISSAM)Sep 9, 2005 - Sep 16, 2008
    Genentech, Inc.
    2004-59 (AVF3290): Primary Systemic Therapy Using Sequential Docetaxel / Cyclophosphamide / Bevacizumab Followed by Adriamycin in Operable/Locally Adv
    Role: Principal Investigator

    20040249 CTA     (MAKHOUL, ISSAM)Jul 12, 2005 - Jul 30, 2008
    Amgen, Inc.
    UARK 2005-09 (Amgen 20040249): A Randomized, Open-label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in th
    Role: Principal Investigator

    ARIA 14906: 9238IL/0065 CTA     (MAKHOUL, ISSAM)Dec 30, 2004 - Feb 5, 2008
    AstraZeneca
    UARK 2004-39: (9238IL/0065) A Randomized, Open-Label, Multicenter, Phase II Study Comparing the Effects on Proliferation and the Efficacy and Tolerabi
    Role: Principal Investigator

    PRN 19395 Budget Amend CTA     (MAKHOUL, ISSAM)Apr 20, 2004 - Apr 20, 2005
    Amgen, Inc.
    UARK 2004-02, A Randomized, Double-blind, Placebo-controlled Study of darbepoetin alfa for the Treatment of Anemia in Subjects with NonMyeloid Maligna
    Role: Principal Investigator

    2003-34     (MAKHOUL, ISSAM)Jan 16, 2004 - Dec 31, 2005
    NOVARTIS Pharmaceuticals Corporation
    UARK 2003-34, CPTK787 0133/304946: A randomized, double-blind, placebo-controlled, phase III study of oxaliplatin / 5-fluorouracil / leucovorin with P
    Role: Principal Investigator

    UARK 2002-17     (MAKHOUL, ISSAM)Mar 27, 2003 - Jul 1, 2004
    Upjohn, Inc.
    UARK 2002-17 A Phase II, Randomized, Open-Label, Controlled, Dose-Evaluation, Multicenter Trial of Thalidomide for the Prevention of Diarrhea Associat
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Taylor EM, Byrum SD, Edmondson JL, Wardell CP, Griffin BG, Shalin SC, Gokden M, Makhoul I, Tackett AJ, Rodriguez A. Proteogenomic analysis of melanoma brain metastases from distinct anatomical sites identifies pathways of metastatic progression. Acta Neuropathol Commun. 2020 09 05; 8(1):157. PMID: 32891176.
      View in: PubMed
    2. Todorova VK, Hsu PC, Wei JY, Lopez-Candales A, Chen JZ, Su LJ, Makhoul I. Biomarkers of inflammation, hypercoagulability and endothelial injury predict early asymptomatic doxorubicin-induced cardiotoxicity in breast cancer patients. Am J Cancer Res. 2020; 10(9):2933-2945. PMID: 33042627.
      View in: PubMed
    3. Hernandez Puente CV, Hsu PC, Rogers LJ, Jousheghany F, Siegel E, Kadlubar SA, Beck JT, Makhoul I, Hutchins LF, Kieber-Emmons T, Monzavi-Karbassi B. Association of DNA-Methylation Profiles With Immune Responses Elicited in Breast Cancer Patients Immunized With a Carbohydrate-Mimicking Peptide: A Pilot Study. Front Oncol. 2020; 10:879. PMID: 32582547.
      View in: PubMed
    4. Fugere T, Chen ZJ, Makhoul I. Practical Vitamin D Supplementation Using Machine Learning. J Bone Metab. 2020 May; 27(2):111-117. PMID: 32572371.
      View in: PubMed
    5. Hsu PC, Kadlubar SA, Siegel ER, Rogers LJ, Todorova VK, Su LJ, Makhoul I. Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer. PLoS One. 2020; 15(4):e0230248. PMID: 32298288.
      View in: PubMed
    6. Joshi K, Atwal D, Ravilla R, Pandey Y, Yarlagadda N, Kakadia S, Makhoul I, Hutchins L, Mahmoud F. Immunotherapy Outcomes in Advanced Melanoma in Relation to Age. Perm J. 2020; 24. PMID: 32097116.
      View in: PubMed
    7. Ananthula A, Lockwood B, Savage J, Malak S, Chen C, Makhoul I, Pennisi A. Primary Breast Carcinoma of the Vulva Metastatic to Lymph Nodes and Bones: A Case Report and Literature Review. Perm J. 2020; 24. PMID: 32097114.
      View in: PubMed
    8. Todorova VK, Siegel ER, Kaufmann Y, Kumarapeli A, Owen A, Wei JY, Makhoul I, Klimberg VS. Dantrolene Attenuates Cardiotoxicity of Doxorubicin Without Reducing its Antitumor Efficacy in a Breast Cancer Model. Transl Oncol. 2020 Feb; 13(2):471-480. PMID: 31918212.
      View in: PubMed
    9. Dillmon MS, Kennedy EB, Anderson MK, Brodersen M, Cohen H, D Amato SL, Davis P, Doshi G, Genschaw S, Makhoul I, Ormsby W, Panikkar R, Peng E, Raez LE, Ronnen EA, Wimbiscus B, Reff M. Patient-Centered Standards for Medically Integrated Dispensing: ASCO/NCODA Standards. J Clin Oncol. 2020 02 20; 38(6):633-644. PMID: 31815576.
      View in: PubMed
    10. Lockwood M, Banderudrappagari R, Suva LJ, Makhoul I. Atypical femoral fractures from bisphosphonate in cancer patients - Review. J Bone Oncol. 2019 Oct; 18:100259. PMID: 31497503.
      View in: PubMed
    11. Galanzha EI, Menyaev YA, Yadem AC, Sarimollaoglu M, Juratli MA, Nedosekin DA, Foster SR, Jamshidi-Parsian A, Siegel ER, Makhoul I, Hutchins LF, Suen JY, Zharov VP. In vivo liquid biopsy using Cytophone platform for photoacoustic detection of circulating tumor cells in patients with melanoma. Sci Transl Med. 2019 06 12; 11(496). PMID: 31189720.
      View in: PubMed
    12. Jamshidi-Parsian A, Griffin RJ, Kore RA, Todorova VK, Makhoul I. Tumor-endothelial cell interaction in an experimental model of human hepatocellular carcinoma. Exp Cell Res. 2018 11 01; 372(1):16-24. PMID: 30205087.
      View in: PubMed
    13. Atwal D, Safar AM, Govindarajan R, Makhoul I. Severe first infusion reaction related to cetuximab in cancer patients in Arkansas. J Oncol Pharm Pract. 2019 Jul; 25(5):1130-1134. PMID: 29890919.
      View in: PubMed
    14. Sherman AC, Simonton-Atchley S, Mikeal CW, Anderson KM, Arnaoutakis K, Hutchins LF, Makhoul I, Mahmoud F, Milojkovic N, Harrington SE, Suen JY. Cancer patient perspectives regarding preparedness for end-of-life care: A qualitative study. J Psychosoc Oncol. 2018 Jul-Aug; 36(4):454-469. PMID: 29863447.
      View in: PubMed
    15. Pashov A, Hernandez Puente CV, Ibrahim SM, Monzavi-Karbassi B, Makhoul I, Kieber-Emmons T. Thinking Cancer. Monoclon Antib Immunodiagn Immunother. 2018 Jun; 37(3):117-125. PMID: 29939836.
      View in: PubMed
    16. Makhoul I, Atiq M, Alwbari A, Kieber-Emmons T. Breast Cancer Immunotherapy: An Update. Breast Cancer (Auckl). 2018; 12:1178223418774802. PMID: 29899661.
      View in: PubMed
    17. Tippit D, Siegel E, Ochoa D, Pennisi A, Hill E, Merrill A, Rowe M, Henry-Tillman R, Ananthula A, Makhoul I. Upper-Extremity Deep Vein Thrombosis in Patients With Breast Cancer With Chest Versus Arm Central Venous Port Catheters. Breast Cancer (Auckl). 2018; 12:1178223418771909. PMID: 29881287.
      View in: PubMed
    18. Atwal D, Ramos JM, Makhoul I. Late breast cancer recurrence with bone marrow metastases and acute pulmonary hypertension. Proc (Bayl Univ Med Cent). 2018 Apr; 31(2):213-215. PMID: 29706824.
      View in: PubMed
    19. Makhoul I, Motwani P, Schafer L, Arnaoutakis K, Mahmoud F, Safar M, Graves D, Mehta P, Govindarajan R, Hutchins L, Thrush C. Integrating Collaborative Learning and Competition in a Hematology/Oncology Training Program. J Cancer Educ. 2018 02; 33(1):186-192. PMID: 27516202.
      View in: PubMed
    20. Yu LR, Cao Z, Makhoul I, Daniels JR, Klimberg S, Wei JY, Bai JP, Li J, Lathrop JT, Beger RD, Todorova VK. Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients. Exp Biol Med (Maywood). 2018 02; 243(3):248-255. PMID: 29224368.
      View in: PubMed
    21. Hutchins LF, Makhoul I, Emanuel PD, Pennisi A, Siegel ER, Jousheghany F, Guo X, Pashov AD, Monzavi-Karbassi B, Kieber-Emmons T. Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects. Oncotarget. 2017 Nov 17; 8(58):99161-99178. PMID: 29228761.
      View in: PubMed
    22. Sonbol MB, Firwana B, Wang Z, Almader-Douglas D, Borad MJ, Makhoul I, Ramanathan RK, Ahn DH, Bekaii-Saab T. Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis. Cancer. 2017 Dec 01; 123(23):4680-4686. PMID: 28817187.
      View in: PubMed
    23. Nima ZA, Alwbari AM, Dantuluri V, Hamzah RN, Sra N, Motwani P, Arnaoutakis K, Levy RA, Bohliqa AF, Nedosekin D, Zharov VP, Makhoul I, Biris AS. Targeting nano drug delivery to cancer cells using tunable, multi-layer, silver-decorated gold nanorods. J Appl Toxicol. 2017 Dec; 37(12):1370-1378. PMID: 28730725.
      View in: PubMed
    24. Firwana B, Avaritt N, Shields B, Ravilla R, Makhoul I, Hutchins L, Tackett AJ, Mahmoud F. Do checkpoint inhibitors rely on gut microbiota to fight cancer? J Oncol Pharm Pract. 2018 Sep; 24(6):468-472. PMID: 28625074.
      View in: PubMed
    25. Mahmoud F, Shields B, Makhoul I, Avaritt N, Wong HK, Hutchins LF, Shalin S, Tackett AJ. Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack. . 2017 Jul 03; 18(7):451-469. PMID: 28513269.
      View in: PubMed
    26. Griffin RJ, Dings RPM, Makhoul I. Further rationale for optimal combined modality treatments. Oncotarget. 2017 04 18; 8(16):25831-25832. PMID: 28415727.
      View in: PubMed
    27. Todorova VK, Makhoul I, Dhakal I, Wei J, Stone A, Carter W, Owen A, Klimberg VS. Polymorphic Variations Associated With Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients. Oncol Res. 2017 Sep 21; 25(8):1223-1229. PMID: 28256194.
      View in: PubMed
    28. Todorova VK, Makhoul I, Wei J, Klimberg VS. Circulating miRNA Profiles of Doxorubicin-induced Cardiotoxicity in Breast Cancer Patients. Ann Clin Lab Sci. 2017 Mar; 47(2):115-119. PMID: 28442511.
      View in: PubMed
    29. Kieber-Emmons T, Monzavi-Karbassi B, Hutchins LF, Pennisi A, Makhoul I. Harnessing benefit from targeting tumor associated carbohydrate antigens. Hum Vaccin Immunother. 2017 02; 13(2):323-331. PMID: 27929800.
      View in: PubMed
    30. Makhoul I, Todorova VK, Siegel ER, Erickson SW, Dhakal I, Raj VR, Lee JY, Orloff MS, Griffin RJ, Henry-Tillman RS, Klimberg S, Hutchins LF, Kadlubar SA. Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients. PLoS One. 2017; 12(1):e0168550. PMID: 28045923.
      View in: PubMed
    31. Kieber-Emmons T, Makhoul I, Pennisi A, Siegel ER, Emanuel PD, Monzavi-Karbassi B, Steplewski Z, Beck JT, Hutchins LF. Managing Expectations in the Transition to Proof of Concept Studies. Rev Recent Clin Trials. 2017; 12(2):111-123. PMID: 28325150.
      View in: PubMed
    32. Shah NN, Klair JS, Makhoul I. Abdominal Compartment Syndrome: Condition Necessitating Prompt Management. J Ark Med Soc. 2017 Jan; 113(7):158-159. PMID: 30085461.
      View in: PubMed
    33. Makhoul I, Yacoub A, Siegel E. Type 2 diabetes mellitus is associated with increased risk of pancreatic cancer: A veteran administration registry study. SAGE Open Med. 2016; 4:2050312116682257. PMID: 28348740.
      View in: PubMed
    34. Bansal M, Abdallah AO, Pennisi A, Arnaoutakis K, Makhoul I, Mehta P. Improving Communication on Intent of Chemotherapy Using QOPI Scores and PDSA Cycles. J Cancer Educ. 2016 12; 31(4):736-741. PMID: 26411307.
      View in: PubMed
    35. Makhoul I. Cancer heterogeneity, patient diversity and next-generation cognitive computing. J Ark Med Soc. 2016 Dec; 113(6):126. PMID: 30047671.
      View in: PubMed
    36. Kaur V, Haider S, Sasapu A, Mehta P, Arnaoutakis K, Makhoul I. Addressing Opioid-Associated Constipation Using Quality Oncology Practice Initiative Scores and Plan-Do-Study-Act Cycles. J Oncol Pract. 2017 01; 13(1):e91-e97. PMID: 28084881.
      View in: PubMed
    37. Todorova VK, Makhoul I, Siegel ER, Wei J, Stone A, Carter W, Beggs ML, Owen A, Klimberg VS. Biomarkers for Presymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients. PLoS One. 2016; 11(8):e0160224. PMID: 27490685.
      View in: PubMed
    38. Pennisi A, Kieber-Emmons T, Makhoul I, Hutchins L. Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast Cancer. Breast Cancer (Auckl). 2016; 10:103-6. PMID: 27478380.
      View in: PubMed
    39. Atrash S, Makhoul I, Mizell JS, Hutchins L, Mahmoud F. Response of metastatic mucosal melanoma to immunotherapy: It can get worse before it gets better. J Oncol Pharm Pract. 2017 Apr; 23(3):215-219. PMID: 26811403.
      View in: PubMed
    40. Monzavi-Karbassi B, Siegel ER, Medarametla S, Makhoul I, Kieber-Emmons T. Breast cancer survival disparity between African American and Caucasian women in Arkansas: A race-by-grade analysis. Oncol Lett. 2016 Aug; 12(2):1337-1342. PMID: 27446434.
      View in: PubMed
    41. Mahmoud F, Abdallah AO, Arnaoutakis K, Makhoul I. Metastatic Renal Cell Carcinoma Presenting as Painful Chewing Successfully Treated with Combined Nivolumab and Sunitinib. Perm J. 2016; 20(3):15-149. PMID: 27352410.
      View in: PubMed
    42. Makhoul I. Health care disparity and the pursuit of happiness. J Ark Med Soc. 2016 Jun; 112(14):268. PMID: 27434978.
      View in: PubMed
    43. Makhoul I, Griffin RJ, Siegel E, Lee J, Dhakal I, Raj V, Jamshidi-Parsian A, Klimberg S, Hutchins LF, Kadlubar S. High-circulating Tie2 Is Associated With Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer. Am J Clin Oncol. 2016 06; 39(3):248-54. PMID: 24577164.
      View in: PubMed
    44. Mahmoud F, Shields B, Makhoul I, Hutchins LF, Shalin SC, Tackett AJ. Role of EZH2 histone methyltrasferase in melanoma progression and metastasis. . 2016 06 02; 17(6):579-91. PMID: 27105109.
      View in: PubMed
    45. Alwbari A, Makhoul I. How I Manage Chronic Lymphocytic Leukemia in 2014. J Ark Med Soc. 2016 Feb; 112(10):187-8. PMID: 26939472.
      View in: PubMed
    46. Makhoul I, Montgomery CO, Gaddy D, Suva LJ. The best of both worlds - managing the cancer, saving the bone. Nat Rev Endocrinol. 2016 Jan; 12(1):29-42. PMID: 26503674.
      View in: PubMed
    47. Rao A, Sasapu A, Jiwani S, Laryea J, Makhoul I. Diffuse large B-cell lymphoma of the colon--a rare presentation. J Ark Med Soc. 2015 Mar; 111(10):208-10. PMID: 25831631.
      View in: PubMed
    48. Makhoul I, Klimberg VS, Korourian S, Henry-Tillman RS, Siegel ER, Westbrook KC, Hutchins LF. Combined neoadjuvant chemotherapy with bevacizumab improves pathologic complete response in patients with hormone receptor negative operable or locally advanced breast cancer. Am J Clin Oncol. 2015 Feb; 38(1):74-9. PMID: 23563210.
      View in: PubMed
    49. Kieber-Emmons T, Pennisi A, Lane A, Siegel E, Cannon M, Monzavi-Karbassi B, Makhoul I. Defining and managing expectations for early immunotherapy cancer trials. Rev Recent Clin Trials. 2015; 10(1):47-60. PMID: 25723736.
      View in: PubMed
    50. Suva LJ, Makhoul I. Bone: Will breast cancer chemoprevention stand on 'solid bone'? Nat Rev Endocrinol. 2015 Mar; 11(3):138-9. PMID: 25511313.
      View in: PubMed
    51. Makhoul I. Surviving cancer as "myself" not as a face of the disease. J Ark Med Soc. 2014 Dec; 111(7):126. PMID: 25668917.
      View in: PubMed
    52. Makhoul I, Hutchins L, Emanuel PD, Pennisi A, Siegel E, Jousheghany F, Monzavi-Karbassi B, Kieber-Emmons T. Moving a Carbohydrate Mimetic Peptide into the clinic. Hum Vaccin Immunother. 2015; 11(1):37-44. PMID: 25483513.
      View in: PubMed
    53. Alwbari A, Makhoul I. How I manage chronic lymphocytic leukemia in 2014. J Ark Med Soc. 2014 Sep; 111(4):68-9. PMID: 25255690.
      View in: PubMed
    54. Pandey S, Nakagawa M, Rosenbaum ER, Arnaoutakis K, Hutchins LF, Makhoul I, Milojkovic N, Cottler-Fox M. Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor. J Clin Apher. 2015 Feb; 30(1):50-4. PMID: 25042026.
      View in: PubMed
    55. Makhoul I. Rethinking cancer screening. J Ark Med Soc. 2014 Jun; 110(13):270. PMID: 25004665.
      View in: PubMed
    56. Batra A, Cottler-Fox M, Harville T, Rhodes-Clark BS, Makhoul I, Nakagawa M. Autologous Graft versus Host Disease: An Emerging Complication in Patients with Multiple Myeloma. Bone Marrow Res. 2014; 2014:891427. PMID: 24876970.
      View in: PubMed
    57. Klimberg VS, Ochoa D, Henry-Tillman R, Hardee M, Boneti C, Adkins LL, McCarthy M, Tummel E, Lee J, Malak S, Makhoul I, Korourian S. Long-term results of phase II ablation after breast lumpectomy added to extend intraoperative margins (ABLATE l) trial. J Am Coll Surg. 2014 Apr; 218(4):741-9. PMID: 24655863.
      View in: PubMed
    58. Makhoul I. Can happiness improve cancer survival? J Ark Med Soc. 2013 Dec; 110(7):126-7. PMID: 24494346.
      View in: PubMed
    59. Makhoul I. Compassionate Medical Care and Efficiency: Are They Compatible?. J Ark Med Soc. 2013.
    60. Govindarajan R, Siegel E, Makhoul I, Williamson S. Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinoma. Am J Clin Oncol. 2013 Jun; 36(3):254-7. PMID: 22643560.
      View in: PubMed
    61. Makhoul I. Compassionate medical care efficiency: are they compatible. J Ark Med Soc. 2013 Jun; 109(13):270. PMID: 23808090.
      View in: PubMed
    62. Makhoul I, Klimberg VS, Korourian S, Henry-Tillman RS, Siegel ER, Westbrook KC, Hutchins LF. Combined Neoadjuvant Chemotherapy With Bevacizumab Improves Pathologic Complete Response in Patients With Hormone Receptor Negative Operable or Locally Advanced Breast Cancer. Am J Clin Oncol. 2013.
    63. Rao KN, Makhoul I. Metastatic colon cancer. Review. Fed Practitioner. 2013.
    64. Makhoul I. Geriatrics. Rehabilitiation Medicine Quick Reference. Blood Disorders. 2013.
    65. Makhoul I. Jumping from the last to the first row: the case for a central role for cancer research in Arkansas. J Ark Med Soc. 2012 Dec; 109(7):126. PMID: 23304844.
      View in: PubMed
    66. Todorova VK, Beggs ML, Delongchamp RR, Dhakal I, Makhoul I, Wei JY, Klimberg VS. Transcriptome profiling of peripheral blood cells identifies potential biomarkers for doxorubicin cardiotoxicity in a rat model. PLoS One. 2012; 7(11):e48398. PMID: 23209553.
      View in: PubMed
    67. Pandey S, Laryea J, Makhoul I, Lamps L, Singh ZN. Synchronous adenocarcinoma and epstein-barr virus-associated polymorphic multifocal ulcerative mucosal lesions in the colon - coincidental or related?. Eur J Clin Med Oncology. 2012.
    68. Makhoul I. The "omics" revolution and personalized medicine. J Ark Med Soc. 2012 Jun; 108(13):288. PMID: 22799130.
      View in: PubMed
    69. Glover-Collins K, Starlard-Davenport A, Makhoul I, Hutchins LF, Lee J, Westbrook K, Korourian S, Enoch K, Preston M, Klimberg VS, Henry-Tillman R. Race not a factor in overall survival in patients with triple negative breast cancer: A retrospective review. American Society of Breast Surgeons. 2012.
    70. Todorova V, Beggs M, Dhakal I, Hennings L, Makhoul I, Klimberg VS. Peripheral blood transcriptomics and doxorubicin cardiotoxicity. San Antonio Breast Cancer Symposium. 2012.
    71. Makhoul I. Winning the War on Cancer: Is it possible?. J Ark Med Society. 2011; 108(7).
    72. Suva LJ, Brander BE, Makhoul I. Update on bone-modifying agents in metastatic breast cancer. Nat Rev Endocrinol. 2011 May 24; 7(7):380-1. PMID: 21610686.
      View in: PubMed
    73. Makhoul I, Kiwan E. Neoadjuvant systemic treatment of breast cancer. J Surg Oncol. 2011 Mar 15; 103(4):348-57. PMID: 21337570.
      View in: PubMed
    74. Yacoub A, Siegel E, Makhoul I. Pancreatic cancer and diabetes mellitus: A retrospective cohort study. J Clin Oncol 29 (suppl). 2011.
    75. Kiwan E, Makhoul I, Siegel E, Hutchins L, Maddox AM, Govindarajan R. Cetuximab-related first infusion reaction rate in cancer patients. American Society for Clinical Oncology Annual Meeting. 2011.
    76. Kyei M, Lavelle E, Kyasa J, Safar M, Makhoul I, Mehta P. Triaging referrals as part of hematology/oncology fellowship training. J Cancer Educ. 2010 Sep; 25(3):437-41. PMID: 20339965.
      View in: PubMed
    77. Kunther A, Safar A, Kyasa MJ, Makhoul I, Harrington S, Mehta P. Addressing End-of-Life Care - When the Patient or Family Doesn't Want to Let Go. Fed Practitioner. 2010; 27(5):34-36.
    78. Suva LJ, Griffin RJ, Makhoul I. Mechanisms of bone metastases of breast cancer. Endocr Relat Cancer. 2009 Sep; 16(3):703-13. PMID: 19443538.
      View in: PubMed
    79. Makhoul I, Klimberg VS, Korourian S, Henry-Tillman RS, Siegel E, Westbrook KC, Hutchins LF. Bevacizumab Combined with Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Operable or Locally Advanced Breast Cancer. Cancer Res. 2009.
    80. Govindarajan R, Siegel E, Makhoul I, Williamson S. Phase II study of efficacy of bevacizumab and erlotinib in inoperable previously untreated hepatocellular carcinoma (HCC). 2009.
    81. Khan M, Makhoul I. Diabetes Mellitus Modulates Age at Onset and Tumor Stage of Hepatocellular Carcinoma. Gastrointestinal Cancers Symposium. 2009.
    82. Govindarajan R, Siegel ER, Makhoul I, Williamson SK. Phase II study of efficacy of bevacizumab and erlotinib in inoperable previously untreated hapatocellular carcinoma (HCC). Gastrointestinal Cancers Symposium. 2009.
    83. Makhoul I, Klimberg VS, Henry-Tillman R, Westbrook K, Hutchins L. Primary Systemic Therapy Using Docetaxel/Cyclophosphamide/Bevacizumab (TCB) Followed by Doxorubicin (A) In Operable or Locally Advanced Breast Cancer (BC). San Antonio Breast Cancer Symposium. 2008.
    84. Makhoul I, Siegel E, Hutchins L, Maddox A-M, Govindarajan R, Safar AM. Cetuximab-Related First Infusion Reaction (FIR) in Colorectal Cancer (CRC) and Other Cancer (CA) Patients (Pts). Gastrointestinal Cancers Symposium. 2008.
    85. Sachdeva K, Makhoul I, Javeed M, Curti B. Renal Cell Carcinoma. eMedicine, eMedicine Specialties: Medicine, OB/Gyn, Psychiatry, and Surgery: Oncology. 2006.
    86. Makhoul I, Javeed M, Ballard J. Spur Cell Anemia. eMedicine, eMedicine Specialties: Medicine, OB/Gyn, Psychiatry, and Surgery: Hematology. 2006.
    87. Makhoul I, Claxton, D, Rybka W. Pure Cell Disorders. eMedicine, eMedicine Specialties: Medicine, OB/Gyn, Psychiatry, and Surgery: Hematology. 2006.
    88. Mansoor M, Ryan CJ, Makhoul I, Sachdeva K, Curti B. Germ Cell Tumors. eMedicine, eMedicine Specialties: Medicine, OB/Gyn, Psychiatry, and Surgery: Oncology. 2006.
    89. Margulies AG, Makhoul I, Henry-Tillman R, Kepple J, Adkins L, Colvert M, Korourian S, Klimberg VS. Tumor Burden in Neoadjuvant Sentinel Lymph Node Biopsy May Predict Response to Chemotherapy. American Surgical Association Meeting. 2005.
    90. Makhoul I, Curti B, Sachdeva K. Extragonadal Germ Cell Tumors. eMedicine, eMedicine Specialties: Medicine, OB/Gyn, Psychiatry, and Surgery: Oncology. 2004.
    91. Makhoul I, Eslinger P, Popescu D, Harvey H, Parkinson K, Lipton A. Effect of Aromatase Inhibitor Therapy on Cognitive Function. ASCO Proceedings. 2004.
    92. Makhoul H, Makhoul I, Claxton D, Ballard J. Combined B-Cell and T-Cell Disorders. eMedicine, eMedicine Specialties: Medicine, OB/Gyn, Psychiatry, and Surgery: Hematology. 2003.
    93. Makhoul I, Harvey H, Delo J, Clinthorne D, Hogaboom K, Lipton A. Phase I/II studty of Topotecan and Gemcitabine in Advanced Metastatic Colorectal Cancer. ASCO Proceedings. 2002.
    94. Makhoul I, Ballard J, Makhoul H. Hypogammaglobulinemia. eMedicine, eMedicine Specialties: Allergy and Immunology. 2002.
    95. Marx JH, Lietzel K, Ali SM, Demers L, Almokadem S, Makhoul I, Carney W, Hamer P, Brady C, Dugan M, Lipton A. Serum EGFR in Metastatic Breast Cancer Patients. ASCO Proceedings. 2002.
    96. Makhoul I, Mierski J, Bongiovani M, Ehmann C, Rybka WB. Suppression of Passenger Lymphocyte Mediated Hemolysis in ABO Minor Mismatched Allogenic Peripheral Blood Hematopoietic Cell Transplantation. ASH Proceedings. 2000.
    97. Makhoul I, Makary AZ. Polyclonal Hyperviscosity Syndrome Secondary to High Rheumatoid Factor Titer From Unknown Etiology. 1998.
    98. Makhoul I, Saul R, Martin S, Pierce R. Pituitary Apoplexy Complicating a Rathke's Cleft Cyst. 1998.
    99. Monchamps G, Riviere B, Hamrouni M, Massart JD, Makhoul I, Picard JP. Specific Emergency Treatment of Shoshin Beriberi and its Metabolic Complications. Presse Medicale. 1989; 18(34):1711-2.
    100. Makhoul I. TSH Receptor: Structure, Methods of Study and Clinical Applications. 1988.
    Makhoul's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _